Table 6.
Antimicrobial susceptibility profiles in this study and previous studies of Salmonella isolates from broiler chickens in Japan
| Antimicrobial agent | MIC break-point (μg/mL) | No. of resistant isolates (%) | ||
|---|---|---|---|---|
| Previous studies | This study | |||
| 2004–2006 (n = 120)a |
2007–2008 (n = 93)b |
2009–2012 (n = 243)c |
||
| SM | ≥16 | 120 (100) | 86 (92.5) | 231 (95.1) |
| OTC | ≥16 | 120 (100) | 86 (92.5) | 222 (91.4) |
| SUL | ≥512 | 120 (100) | 86 (92.5) | 221 (91.0) |
| AMP | ≥32 | 29 (22.4) | 34 (36.5) | 134 (55.1) |
| CTX | ≥4 | 11 (9.1) | 33 (35.5) | 128 (52.7) |
| KM | ≥64 | 9 (7.5) | 12 (12.9) | 16 (6.6) |
| CFX | ≥32 | 0 (0.0) | 8 (8.6) | 15 (6.2) |
| OFLX | ≥2 | 25 (20.8) | 11 (11.8) | 4 (1.6) |
| CP | ≥32 | 0 (0.0) | 0 (0.0) | 0 (0.0) |
AMP ampicillin, CTX cefotaxime, CFX cefoxitin, CP chloramphenicol, SM streptomycin, SUL sulfamethoxazole, OTC oxytetracycline, KM kanamycin, OFLX ofloxacin
aCited from [15]
bCited from [14]
cThis study
*Significantly increased from the period of 2004–2006 (p < 0.05)
# Significantly increased from the period of 2007–2008 (p < 0.05)
$Significantly decreased from the period of 2004–2006 (p < 0.05)